The All-In-One Guru Screener,can be used to find the most insider buys over the past week by clicking on the Insiders tab and changing the settings for All Insider Buying to "1,000,000+ shares at $5,000,000" and Duration to "over the past 14 days."
Over the last 7 days, the most bought companies are Chesapeake Energy Corp (CHK) and Cocrystal Pharma Inc (COCP).
On March 27, 2015, Director Archie W. Dunham, purchased 1,000,000 shares of Chesapeake Energy Corp, with a total cost of $13,980,000. Since then, the price rose by +4.4%.
Thanks to this buy (that is the most weighted one since December 14, 2005 when Chairman & CEO, MCCLENDON AUBREY K bought 750,000 shares) Archie W. Dunham became the third Direct Holder of CHKwith 0.25% of Shares Outstanding, after President & COO Tom L. Ward (2.11%) and Chairman & CEO, Director Aubrey K. McClendon (0.48%).
CHK has an institutional ownership of 90.0% and an insider ownership of 4.0%.
CHKÂ has a market cap of $9,703 million. Over the last year, the price dropped by 42% and is currently trading at a P/E (ttm) of 9.40, better then 91% of the Global Oil & Gas E & P Industry’s competitors.
The company has a good financial strength and the Cash to Debt ratio (0.36) is at the best levels of LPI History. Profitability & Growth is rated 8/10 with ratios better then 86% of competitors (11.73% of ROE, 4.64% of ROA, 9.67% of ROC).
Even if Result may not be accurate due to the low predictability of business, the company looks Undervalued based on the Discounted Cash Flow Model that suggest a fair price of 22.13$ with a current Margin of Safety of 34%.
CHKÂ is mostly held by Mason Hawkins (11.11% of Shares Outstanding) and Carl Icahn (9.99%).
On March 25, 2015, Director and 10% Owner Frost Phillip MD, purchased 3,464,855 shares for a total cost of $3,187,670, together with Director Hsiao Jane Ph D. who purchased 2,200,000 shares with a total cost of $2,024,000 of Cocrystal Pharma Inc (COCP). Since then, the price rose by +56.5%.
COCP has an institutional ownership of 15.0% and an insider ownership of 1.0%.
COCPÂ has a market cap of $970 million. Over the last year, the price rose by +156% and is currently trading at a P/B of 48.50, better then 55% of companies in the Global Pharmaceutical Retailers Industry.
The company has a good financial strength rated 7/10 and has No Debts. Profitability & Growth is weak. It is rated 4/10 with heavy negative ratios (-149.79% of ROA, -514.69% of ROC).
COCP is not held by any Guru.
